Cowen & Co. analyst Boris Peaker maintained a Hold rating on Tesaro (NASDAQ: TSRO) yesterday and set a price target of $52. The company’s shares closed yesterday at $42.56, close to its 52-week low of $42.13.
According to TipRanks.com, Peaker is a 5-star analyst with an average return of 16.6% and a 51.2% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Stemline Therapeutics Inc, Mersana Therapeutics Inc, and Jounce Therapeutics Inc.
Currently, the analyst consensus on Tesaro is Moderate Buy and the average price target is $83.43, representing a 96.0% upside.
In a report issued on May 30, Jefferies also maintained a Hold rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $153.98 and a one-year low of $42.13. Currently, Tesaro has an average volume of 1.29M.
Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TESARO, Inc. is an oncology-focused biopharmaceutical company, which engages in the research and development of biopharmaceutical products. It focuses on oncology-based therapeutics and its products include: Rolapitant and Niraparib.
